BAP Health Outcomes Research1 and Department of Medicine, Universidad de Oviedo, Oviedo, Spain.
Perit Dial Int. 2012 Mar-Apr;32(2):192-9. doi: 10.3747/pdi.2011.00037. Epub 2011 Sep 30.
We undertook a cost-effectiveness analysis of the Spanish Renal Replacement Therapy (RRT) program for end-stage renal disease patients from a societal perspective. The current Spanish situation was compared with several hypothetical scenarios.
A Markov chain model was used as a foundation for simulations of the Spanish RRT program in three temporal horizons (5, 10, and 15 years). The current situation (scenario 1) was compared with three different scenarios: increased proportion of overall scheduled (planned) incident patients (scenario 2); constant proportion of overall scheduled incident patients, but increased proportion of scheduled incident patients on peritoneal dialysis (PD), resulting in a lower proportion of scheduled incident patients on hemodialysis (HD) (scenario 3); and increased overall proportion of scheduled incident patients together with increased scheduled incidence of patients on PD (scenario 4).
The incremental cost-effectiveness ratios (ICERs) of scenarios 2, 3, and 4, when compared with scenario 1, were estimated to be, respectively, -€83 150, -€354 977, and -€235 886 per incremental quality-adjusted life year (ΔQALY), evidencing both moderate cost savings and slight effectiveness gains. The net health benefits that would accrue to society were estimated to be, respectively, 0.0045, 0.0211, and 0.0219 ΔQALYs considering a willingness-to-pay threshold of €35 000/ΔQALY.
Scenario 1, the current Spanish situation, was dominated by all the proposed scenarios. Interestingly, scenarios 3 and 4 showed the best results in terms of cost-effectiveness. From a cost-effectiveness perspective, an increase in the overall scheduled incidence of RRT, and particularly that of PD, should be promoted.
我们从社会角度对西班牙终末期肾病患者的肾脏替代治疗(RRT)计划进行了成本效益分析。将当前西班牙的情况与几种假设情况进行了比较。
使用马尔可夫链模型作为模拟西班牙 RRT 计划的基础,模拟时间跨度为 5、10 和 15 年。将当前情况(情景 1)与三种不同情景进行了比较:增加所有计划(计划)事件患者的比例(情景 2);所有计划事件患者的比例保持不变,但腹膜透析(PD)计划事件患者的比例增加,导致血液透析(HD)计划事件患者的比例降低(情景 3);以及所有计划事件患者的比例增加,加上 PD 计划事件患者的发病率增加(情景 4)。
与情景 1 相比,情景 2、3 和 4 的增量成本效益比(ICER)分别估计为-€83 150、-€354 977 和-€235 886 每增加一个质量调整生命年(ΔQALY),这表明既节省了成本又略微提高了效果。如果将支付意愿阈值设定为 35 000 欧元/ΔQALY,则估计社会将分别获得 0.0045、0.0211 和 0.0219 ΔQALY 的净健康收益。
情景 1,即当前西班牙的情况,被所有提议的情景所主导。有趣的是,情景 3 和 4 在成本效益方面表现最佳。从成本效益的角度来看,应促进 RRT 的总体计划发病率增加,特别是 PD 的发病率增加。